Ruth Peters

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6148361/publications.pdf

Version: 2024-02-01

76 papers	4,305 citations	172457 29 h-index	114465 63 g-index
77 all docs	77 docs citations	77 times ranked	6427 citing authors

#	Article	IF	Citations
1	Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology, The, 2008, 7, 683-689.	10.2	659
2	Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care, 2016, 39, 300-307.	8.6	450
3	The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. Age and Ageing, 2016, 45, 14-21.	1.6	319
4	Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age and Ageing, 2008, 37, 505-512.	1.6	317
5	No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Medicine, 2015, 13, 78.	5.5	244
6	Updating the Evidence on the Association between Serum Cholesterol and Risk ofÂLate-Life Dementia: Review andÂMeta-Analysis. Journal of Alzheimer's Disease, 2017, 56, 215-228.	2.6	226
7	Literature Review of the Clock Drawing Test as a Tool for Cognitive Screening. Dementia and Geriatric Cognitive Disorders, 2009, 27, 201-213.	1.5	177
8	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5. JAMA Internal Medicine, 2017, 177, 1498.	5.1	158
9	Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis. BMJ Open, 2019, 9, e022846.	1.9	138
10	Validity of the Clock-Drawing Test as a Screening Tool for Cognitive Impairment in the Elderly. American Journal of Epidemiology, 2004, 160, 797-807.	3.4	112
11	A Systematic Review of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the Quantity, Quality, and Global Representativeness of Evidence. Journal of Alzheimer's Disease, 2019, 70, S165-S186.	2.6	98
12	Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231988039.	2.5	98
13	Does additional feeding support provided by health care assistants improve nutritional status and outcome in acutely ill older in-patients?â€"a randomised control trial. Clinical Nutrition, 2004, 23, 69-77.	5.0	97
14	Investigation of antihypertensive class, dementia, and cognitive decline. Neurology, 2020, 94, e267-e281.	1.1	78
15	The effect of treatment based on a diuretic (indapamide) Â ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age and Ageing, 2010, 39, 609-616.	1.6	77
16	Association of sex differences in dementia risk factors with sex differences in memory decline in a population-based cohort spanning 20â€"76Âyears. Scientific Reports, 2021, 11, 7710.	3.3	56
17	Toward a theoryâ€based specification of nonâ€pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations. Alzheimer's and Dementia, 2021, 17, 255-270.	0.8	55
18	Association Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis. Hypertension, 2021, 78, 1478-1489.	2.7	53

#	Article	IF	Citations
19	Trajectory of blood pressure, body mass index, cholesterol and incident dementia: systematic review. British Journal of Psychiatry, 2020, 216, 16-28.	2.8	52
20	Anti-inflammatories in Alzheimerâ€™s diseaseâ€"potential therapy or spurious correlate?. Brain Communications, 2020, 2, fcaa109.	3.3	52
21	Blood pressure and dementia. Neurology, 2019, 92, 1017-1018.	1.1	51
22	Is air pollution associated with increased risk of cognitive decline? A systematic review. Age and Ageing, 2015, 44, 755-760.	1.6	47
23	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	3.9	47
24	The prevention of dementia. International Journal of Geriatric Psychiatry, 2009, 24, 452-458.	2.7	43
25	Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation. Journal of Neuroscience, 2021, 41, 3025-3038.	3.6	41
26	What does (low) education mean in terms of dementia risk? A systematic review and meta-analysis highlighting inconsistency in measuring and operationalising education. SSM - Population Health, 2020, 12, 100654.	2.7	37
27	Predictive Value of the Clock Drawing Test. Dementia and Geriatric Cognitive Disorders, 2008, 26, 351-355.	1.5	35
28	Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. Age and Ageing, 2009, 38, 521-527.	1.6	32
29	Hypertension, dementia, and antihypertensive treatment: Implications for the very elderly. Current Hypertension Reports, 2009, 11, 277-282.	3.5	31
30	Left ventricular hypertrophy is a predictor of cardiovascular events in elderly hypertensive patients. Journal of Hypertension, 2016, 34, 2280-2286.	0.5	29
31	Joining forces to prevent dementia: The International Research Network On Dementia Prevention (IRNDP). International Psychogeriatrics, 2017, 29, 1757-1760.	1.0	28
32	Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. Current Hypertension Reports, 2016, 18, 67.	3.5	27
33	Intergenerational Programmes bringing together community dwelling non-familial older adults and children: A Systematic Review. Archives of Gerontology and Geriatrics, 2021, 94, 104356.	3.0	24
34	Antihypertensive drug use and risk of cognitive decline in the very old. Journal of Hypertension, 2015, 33, 2156-2164.	0.5	22
35	Literature review of visual representation of the results of benefitâ€"risk assessments of medicinal products. Pharmacoepidemiology and Drug Safety, 2016, 25, 238-250.	1.9	22
36	Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus. Journal of Alzheimer's Disease, 2020, 78, 3-12.	2.6	22

#	Article	IF	Citations
37	Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Therapeutic Advances in Chronic Disease, 2015, 6, 160-169.	2.5	19
38	Development of the First WHO Guidelines for Risk Reduction of Cognitive Decline and Dementia: Lessons Learned and Future Directions. Frontiers in Neurology, 2021, 12, 763573.	2.4	19
39	Dementia Risk Scores and Their Role in the Implementation of Risk Reduction Guidelines. Frontiers in Neurology, 2021, 12, 765454.	2.4	18
40	Fracture risk and the use of a diuretic (indapamide sr) Â± perindopril: a substudy of the Hypertension in the Very Elderly Trial (HYVET). Trials, 2006, 7, 33.	1.6	17
41	Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies. Current Hypertension Reports, 2016, 18, 66.	3.5	17
42	Modelling Cognitive Decline in the Hypertension in the Very Elderly Trial [HYVET] and Proposed Risk Tables for Population Use. PLoS ONE, 2010, 5, e11775.	2.5	15
43	Evaluation of High Cholesterol and Risk of Dementia and Cognitive Decline in Older Adults Using Individual Patient Meta-Analysis. Dementia and Geriatric Cognitive Disorders, 2021, 50, 318-325.	1.5	15
44	Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. International Psychogeriatrics, 2009, 21, 359.	1.0	14
45	Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study. International Psychogeriatrics, 2018, 30, 1345-1354.	1.0	14
46	More evidence is needed. Iron, incident cognitive decline and dementia: a systematic review. Therapeutic Advances in Chronic Disease, 2018, 9, 241-256.	2.5	14
47	Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An inâ€depth exploration of seven established risk factors. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12202.	3.7	12
48	Advancing dementia prevention through effective blood pressure control. Lancet Neurology, The, 2020, 19, 25-27.	10.2	9
49	Diastolic Blood Pressure Variability in Later Life May Be a Key Risk Marker for Cognitive Decline. Hypertension, 2022, 79, 1037-1044.	2.7	9
50	Intergenerational Practice in the Communityâ€"What Does the Community Think?. Social Sciences, 2021, 10, 374.	1.4	8
51	Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532211049.	2.7	8
52	The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?. Alzheimer's and Dementia, 2022, 18, 507-512.	0.8	7
53	Baseline characteristics of participants in the Hypertension in the Very Elderly Trial (HYVET). Blood Pressure, 2009, 18, 17-22.	1.5	6
54	Putting Fine Particulate Matter and Dementia in the Wider Context of Noncommunicable Disease: Where are We Now and What Should We Do Next: A Systematic Review. Neuroepidemiology, 2021, 55, 253-265.	2.3	6

#	Article	IF	Citations
55	Development of the CogDrisk tool to assess risk factors for dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	5
56	Frailty in Indigenous Populations: A Scoping Review. Frontiers in Public Health, 2021, 9, 785460.	2.7	4
57	Hypertension in the very elderly. Aging Health, 2007, 3, 517-525.	0.3	3
58	Gender differences in cognitive development in cohorts of young, middle, and older adulthood over 12 years.. Developmental Psychology, 2021, 57, 1403-1410.	1.6	3
59	Committee on Highâ€quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimer's and Dementia, 2022, 18, 1109-1118.	0.8	3
60	Antihypertensive Treatment After Diagnosis of Alzheimer's Disease. American Journal of Hypertension, 2009, 22, 1031-1031.	2.0	1
61	Limitations, including the misclassification of former drinkers. Addiction Research and Theory, 2013, 21, 196-197.	1.9	1
62	No clear relationship between antihypertensive class and cognitive function over 12 months in a cohort study of community-dwelling adults aged 80 and over. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231882084.	2.5	1
63	Higher diastolic blood pressure aged 40â€44 is associated with declining cognition and increasing white matter lesions over 8â€12 year follow up.. Alzheimer's and Dementia, 2020, 16, e045569.	0.8	1
64	Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis. Hypertension, 2020, 76, .	2.7	1
65	Blood pressure change and cognition in childhood and early adulthood: a systematic review. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210851.	2.5	1
66	The clock drawing test, mortality, incident cardiovascular events and dementia. International Journal of Geriatric Psychiatry, 2015, 30, 416-421.	2.7	0
67	Antihypertensive treatment decreases arterial stiffness at night but not during the day. Results from the Hypertension in the Very Elderly Trial. Blood Pressure, 2017, 26, 109-114.	1.5	0
68	Greater cognitive decline relative to normal ageing occurs at least 10 years prior to clinical dementia diagnosis. BMJ Evidence-Based Medicine, 2018, 23, 79-79.	3.5	0
69	P3â€589: HIGH URIC ACID ASSOCIATED WITH REDUCED RISK OF COGNITIVE DECLINE IN HYPERTENSIVE OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1352.	0.8	0
70	Subjective memory decline and neuropsychological performance. Alzheimer's and Dementia, 2020, 16, e045656.	0.8	0
71	THE ASSESSMENT OF QUALITY OF LIFE IN THE HYPERTENSION IN THE VERY ELDERLY (HYVET) TRIAL. Journal of Hypertension, 2004, 22, S96.	0.5	0
72	CHANGE IN COGNITIVE FUNCTION WITHIN THE FIRST YEAR OF ENTERING THE HYPERTENSION IN THE VERY ELDERLY TRIAL (HYVET). Journal of Hypertension, 2004, 22, S54-S55.	0.5	0

#	Article	IF	Citations
73	No clear associations between subjective memory concerns and subsequent change in cognitive function: the PATH through life study. European Journal of Ageing, 0, , 1.	2.8	0
74	Incidence and prevalence of coexistent retinal diseases and cognitive impairment or dementia: A systematic review. Alzheimer's and Dementia, 2021, 17, .	0.8	0
75	Evaluation of blood pressure and cognitive function using individual participant data metaâ€analysis: The Lifeâ€Course Blood Pressure Cognition (LCBPâ€COG) study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
76	Left ventricular hypertrophy and incident cognitive impairment in elderly hypertensive patients: Hypertension in the Very Elderly Trial. Alzheimer's and Dementia, 2021, 17, .	0.8	0